Frequently Asked Questions

An imaging core lab is a central facility that standardizes image acquisition across trial sites, receives and quality-checks every examination, and provides blinded, independent interpretation by qualified readers according to the imaging charter. Intrinsic Imaging fulfills these responsibilities to generate consistent, unbiased imaging endpoints for regulatory evaluation.

Engaging an imaging core lab such as Intrinsic Imaging is warranted when imaging supports a primary or key secondary endpoint, a trial spans multiple sites or scanner types, or the design requires blinded independent central review. Engaging Intrinsic Imaging is also warranted when a medical device or AI/CAD product is evaluated against an expert reference standard.

Sponsors should ideally engage Intrinsic Imaging before finalizing the protocol and imaging schedule. Early scientific and operational review clarifies acquisition requirements, endpoint feasibility and central-reading dependencies. Intrinsic Imaging can also assume responsibility for an active study through a controlled transfer.

Yes. Intrinsic Imaging collaborates with the sponsor’s clinical CRO through a responsibility matrix agreed at study startup. The matrix defines site communication, query ownership, safety escalation and data transfers among Intrinsic Imaging, the sponsor and the clinical CRO.

Intrinsic Imaging establishes working interfaces with the sponsor’s clinical operations, data management and medical monitoring teams. A responsibility matrix defines site communication, query ownership, safety escalation and data transfers. Intrinsic Imaging structures the engagement around clear accountability, documented handoffs and an agreed closeout package.

Yes. Intrinsic Imaging supports Class I–III medical device trials and stand-alone and multi-reader multi-case AI/CAD observer performance studies. Intrinsic Imaging’s services include controlled case handling, reader training, blinded assessments and traceable imaging evidence aligned with the medical device’s intended use and study protocol.

Intrinsic Imaging selects readers from a network of 650+ board-certified and fellowship-trained physicians according to therapeutic expertise and the study’s assessment requirements. Intrinsic Imaging provides protocol-specific training on the imaging charter, applicable criteria and documented review procedures before assessments begin.

Intrinsic Imaging’s typical turnaround times are 24–48 hours for image quality control, 24–72 hours for eligibility and safety reads, and 5–10 business days per batch for efficacy reads. Intrinsic Imaging agrees standard and expedited timelines with the sponsor, documents those timelines in the imaging charter and monitors performance throughout the study.

Intrinsic Imaging agrees the closeout package with the sponsor for each engagement. Intrinsic Imaging’s deliverables include validated imaging data transfers, central-review datasets and audit-ready documentation, supported by imaging data reconciliation and adjudication workflows. These outputs support the sponsor’s regulatory submission and subsequent inspections.

Intrinsic Imaging holds five BSI ISO certifications covering ISO 9001, ISO 13485, ISO 22301, ISO/IEC 27001 and ISO/IEC 27018. Intrinsic Imaging established a quality management system in 2011 and completed three FDA Bioresearch Monitoring inspections in 2012, 2018 and 2021, each concluding with zero Form FDA 483 observations.

Intrinsic Imaging’s five BSI ISO certifications underpin controlled processes for quality, security and business continuity. Intrinsic Imaging maintains study documentation, image-handling records and assessment records for full traceability and audit readiness, supporting sponsor submissions to authorities such as the FDA, EMA and PMDA.

Intrinsic Imaging’s services encompass imaging protocol and charter development, site qualification and training, acquisition standardization, secure image collection, quality control, independent central reads, adjudication and imaging data management. Intrinsic Imaging defines the scope around the study’s imaging endpoints and delivery milestones.

Yes. Sponsors may engage Intrinsic Imaging for a complete imaging workstream or selected activities, including acquisition guidance, site qualification, quantitative analysis, independent reads or study transfer. Intrinsic Imaging documents responsibilities and working interfaces at study kickoff.

Yes. Intrinsic Imaging supports decentralized and hybrid trials through remote site qualification, site training and secure cloud-based image upload. Intrinsic Imaging evaluates portable imaging workflows against protocol requirements, equipment suitability and acquisition quality standards before use.

Intrinsic Imaging establishes protocol-specific acquisition guidelines, evaluates site equipment and trains imaging personnel before activation. Intrinsic Imaging’s central quality-control process verifies incoming images for completeness and acquisition compliance, while documented site queries address issues that could affect endpoint assessment.

Intrinsic Imaging structures blinded independent central review according to the assessment criteria, reader qualifications, blinding requirements and read paradigm defined in the imaging charter. Intrinsic Imaging’s subspecialty readers evaluate images independently through single-, double- or triple-read designs and adjudication workflows selected to satisfy the protocol’s requirements.

Intrinsic Imaging tracks missing and non-evaluable scans against the expected visit schedule, distinguishes technical failures from missing examinations, and applies the protocol’s query and analysis rules. Intrinsic Imaging does not designate a scan as evaluable merely to complete a dataset.

Intrinsic Imaging agrees deliverables with the sponsor in the imaging charter and data transfer specifications. Intrinsic Imaging’s deliverables may include reader assessments, quantitative imaging measurements, adjudicated results, reconciled imaging datasets and supporting documentation, with traceability from image receipt through final delivery.

Intrinsic Imaging defines the starting and completion points for each process step. For charter development, the interval runs from study kickoff to charter sign-off. For image receipt confirmation, the interval runs from site upload to confirmation; for efficacy reading, the interval runs from batch lock to completed reader assessments.

Intrinsic Imaging typically finalizes the imaging charter within about 20 business days of kickoff and prepares the reading system within about 15 business days. Intrinsic Imaging agrees the dependencies and sequence for these distinct startup milestones with the sponsor for each study.

Intrinsic Imaging typically confirms image receipt on the same business day as site upload and issues a quality-control result or query within 24–48 hours of upload. Intrinsic Imaging measures the quality-control milestone at issuance of the result or query, rather than at resolution of every outstanding site query.

Intrinsic Imaging typically completes eligibility and safety reads within 24–72 hours after a case passes quality control. Intrinsic Imaging’s efficacy and endpoint reads typically require 5–10 business days per locked read batch. Adjudication and final delivery follow the imaging charter’s data-cutoff and closeout schedule.

No. Intrinsic Imaging’s published turnaround figures represent typical expectations rather than fixed timelines for every trial. Intrinsic Imaging agrees standard and expedited timelines with the sponsor, documents those timelines in the imaging charter and monitors performance throughout the study, taking into account the protocol, case volume, image readiness and delivery milestones.

Intrinsic Imaging’s technology workflow accommodates DICOM and other study imaging across CT, MRI, PET/CT, SPECT, radiography, ultrasound, echocardiography, DXA, OCT, fundus imaging, angiography, endoscopy and protocol-specific formats. Intrinsic Imaging selects configurations, quality checks and assessment tools for each study rather than imposing a single generic workflow.

Yes. Intrinsic Imaging supports decentralized and hybrid trials by remotely qualifying facilities closer to participants, including community hospitals and regional imaging centers, through equipment surveys, test submissions and virtual training. Qualified sites upload images securely via the cloud. Intrinsic Imaging applies the same central quality-control and blinded-review requirements regardless of where the participant was scanned.

Intrinsic Imaging configures each study according to the protocol, imaging charter and data-transfer requirements. Intrinsic Imaging defines visits, modalities, expected submissions, quality checks, reader roles, blinding, assessment forms, adjudication rules and outputs to establish the basis for controlled setup and verification.

Intrinsic Imaging protects imaging records throughout intake, review and retention through secure transfer, de-identification controls, role-based access and controlled handling. Intrinsic Imaging uses study identifiers to preserve the clinical relationships among participants, visits, images and assessments without exposing information that a user is not authorized to view.

Intrinsic Imaging’s risk-based validation approach links intended use, requirements, study configuration and verification evidence. Intrinsic Imaging applies GAMP 5 principles and relevant FDA expectations to functions that safeguard participant safety, blinding, endpoint integrity and regulated electronic records.

Yes. Intrinsic Imaging supports independent blinded review through study-specific roles and visibility rules for single-, double- and triple-read designs, over-reads and adjudication. Intrinsic Imaging configures the review sequence to govern the information available to each reader and the conditions under which a case advances to the next step.

Intrinsic Imaging’s study reporting can present expected and received examinations, quality-control status, open site queries, reading progress, adjudications and delivery readiness. Intrinsic Imaging defines the reporting scope and cadence according to the study’s oversight requirements.

Yes. Intrinsic Imaging transfers imaging data to sponsor systems according to agreed data-transfer specifications that define identifiers, field mappings, units, precision, file structure, delivery method and reconciliation. Intrinsic Imaging works with each sponsor to define the appropriate interface rather than presuming a universal integration.

Intrinsic Imaging’s final deliverables are defined by the protocol and transfer specification and may include reconciled central-review data, imaging assessments, quantitative results, adjudication outcomes and supporting documentation. Intrinsic Imaging performs release checks to confirm that delivered data agree with the controlled source assessments.

ISO 9001 provides the quality management foundation for Intrinsic Imaging’s imaging services rather than prescribing a particular imaging technique. Intrinsic Imaging uses this framework to define processes, maintain controlled documentation, measure performance and address the causes of problems. The emphasis is on consistent service delivery and continual improvement across clinical image management and radiological review.

No. Intrinsic Imaging’s ISO 13485 certification concerns the quality management system supporting imaging services for medical device clinical trials; it is not approval of a sponsor’s product. Intrinsic Imaging does not manufacture medical devices, and the certification addresses controlled processes for generating imaging evidence. A regulatory decision on a medical device remains separate from certification of the imaging service provider’s management system.

ISO 22301 addresses preparation for disruptive incidents, response and recovery of affected activities. Intrinsic Imaging’s business continuity management system considers dependencies including facilities, telecommunications, technology and external service providers. Documented continuity arrangements support a controlled response when these dependencies are disrupted, with study-specific priorities guiding recovery rather than an assumption that every interruption has the same operational impact.

ISO/IEC 27001 addresses information security risks affecting confidentiality, integrity and availability. Intrinsic Imaging’s information security management system uses controls selected and justified through documented risk assessment and subject to audit. These controls support restricted access, preserved blinding and traceable imaging records, protecting both confidential information and the reliability of the evidence used in a clinical trial.

ISO/IEC 27018 extends information security management with privacy obligations for organizations processing personal data in public clouds on behalf of others. Intrinsic Imaging’s certification applies to personal information processed in cloud-hosted imaging workloads. The framework addresses processing instructions, transparency about sub-processors and controlled handling of data at the end of an engagement, complementing the security controls established under ISO/IEC 27001.

No. GAMP 5 is ISPE’s good-practice guidance for a risk-based lifecycle approach to compliant GxP computerized systems; it is neither a regulation nor a certification. GAMP 5 does not confer FDA approval or supersede applicable regulations. Intrinsic Imaging’s five ISO certifications are distinct from this validation framework.

No. FDA’s Computer Software Assurance for Production and Quality Management System Software guidance addresses software used in medical device production or quality management systems, rather than every clinical trial system. Intrinsic Imaging evaluates clinical investigation systems against the applicable requirements and FDA’s guidance on electronic systems in clinical investigations.

No. Intrinsic Imaging evaluates a platform’s technical features alongside regulatory applicability, intended use, configuration, user permissions, operating procedures, training and retained evidence. Describing a platform as Part 11 compliant does not establish that a particular study workflow is validated or that every applicable requirement is satisfied.

Yes. Intrinsic Imaging evaluates cloud-hosted systems against applicable validation and record-control obligations, which remain in force regardless of hosting location. Qualification considers the service provider, configuration, interfaces, security, changes, recovery, retention and access to records. The evidence must address the actual intended use and the responsibilities assigned to each organization.

No. Supplier documentation can contribute to Intrinsic Imaging’s validation evidence, but it does not replace study-specific verification. Suitability depends on intended use, configuration, interfaces and risk. Intrinsic Imaging evaluates reusable supplier evidence alongside the verification required for the actual imaging workflow.

Yes. Intrinsic Imaging’s validation scope extends to study-specific configuration because read sequencing, access permissions, measurement rules, visit mappings and export formats can affect record reliability even when the underlying software is unchanged. Intrinsic Imaging addresses these settings and the risks introduced by the configured workflow within the validation scope.

No. Intrinsic Imaging determines the extent of revalidation through a documented change-impact assessment rather than assuming that every software update requires complete revalidation. Verification and regression testing address the affected requirements, controls, functions and risks. Intrinsic Imaging documents the release decision before using the changed system.

Intrinsic Imaging’s validation evidence includes the system’s intended use and configuration, requirements, risk assessment, supplier review, verification traceability, test results, assessed deviations and release decision. Intrinsic Imaging’s change-control, training, access-administration, audit-trail review, recovery and retention arrangements document how the validated state is maintained.

Yes. Intrinsic Imaging conducts stand-alone and multi-reader multi-case observer performance studies, drawing on experience from 55 large MRMC AI/CAD studies.

Intrinsic Imaging supports AI clinical validation through protocol and imaging study design collaboration, case selection, dataset development, reference-standard establishment, reader recruitment and qualification, image and data quality control, reader training, blinded execution, adjudication and final data delivery.

Intrinsic Imaging’s screening and triage study evaluated standalone software output against the reference standard on a locked case set, while a fully crossed MRMC design assessed readers using the software as a second read. These assessments address algorithm output in isolation and its interaction with clinical judgment, respectively. Accurate standalone classification therefore does not, by itself, establish improved reader performance.

Intrinsic Imaging’s CAD study with more than 14400 reviews used an independent panel and documented adjudication to establish the reference standard. That common comparison target supported classification of findings across assistance conditions, while the reading platform preserved the sequence of unaided and aided decisions. Independence of the reference determination and control of the reading sequence address different aspects of the comparison.

Intrinsic Imaging selects reader panels according to the clinical indication, imaging modality, intended use and regulatory objectives. Intrinsic Imaging draws on more than 650 board-certified, fellowship-trained physicians to assemble appropriately qualified panels.

Intrinsic Imaging’s MRMC case study describes standardized software and scoring training using cases outside the study set. This approach allows readers to become familiar with the assessment task without rehearsing the cases used to evaluate performance. Intrinsic Imaging also controlled the reading sequence and documented each assessment’s relationship to its case, assistance condition and independently established reference standard.

Intrinsic Imaging’s chest AI case study describes randomized reading sequences and a defined washout interval between sessions to reduce recall bias. Randomization addresses systematic ordering effects, while the interval separates repeated exposure to the same cases. Intrinsic Imaging documented session completion and deviations against the reading protocol; the appropriate interval and sequence remain specific to the study design.

A mammography AI reader study needs to evaluate how radiologists use the software, not only the algorithm’s standalone performance. Intrinsic Imaging’s Guidance highlights prespecified reader experience, case enrichment, washout periods and reading conditions in multi-reader, multi-case designs. It also emphasizes appropriate mammography modalities and vendors, robust reference standards, and assessment of recall and specificity alongside sensitivity rather than detection gains alone.

The dataset and endpoints should reflect whether a study evaluates diagnostic performance, reading workflow or screening benefit. Intrinsic Imaging’s Guidance cautions that survival alone is vulnerable to lead-time and length-time bias and distinguishes mortality, stage shift and validated diagnostic endpoints. It also emphasizes an eligible screening population, pathology or follow-up-based reference standards, and measurement of false positives and downstream procedures, not reader performance alone.

Intrinsic Imaging’s screening and triage study documented a prevalence-enrichment plan and selected cases from multiple institutions to represent scanner, demographic and acquisition variability. The case narrative distinguishes discrimination in that selected population from performance in routine screening. Predictive values cannot be transferred directly from an enriched sample to everyday practice, and the apparent frequency of positive findings can influence reader expectations.

Intrinsic Imaging has supported multiple FDA-cleared AI/CAD/Viewer technologies and completed an MRMC AI/CAD/Viewer trial inspection with zero Form FDA 483 observations. Intrinsic Imaging maintains ISO 13485 certification for medical device clinical trial services. Clearance decisions rest solely with the FDA.

Intrinsic Imaging’s experience encompasses implanted medical devices, stents, catheters, embolization and stroke medical devices, drug delivery medical devices, biopsy equipment, biologics, and AI/CAD/diagnostic software.

Intrinsic Imaging supports 510(k), De Novo and PMA submissions for Class I, II and III medical devices.

Yes. Intrinsic Imaging’s ISO 13485 certification covers the provision of imaging core lab services for medical device trials.

Intrinsic Imaging’s multicenter vascular medical device study defined acquisition and measurement conventions for procedural angiography, CT angiography and duplex ultrasound. Central review included three-dimensional CT reconstruction, and each delivered measurement retained its modality identification. The case explains that co-registration supports anatomical comparison without making measurements from different techniques inherently equivalent, preserving the distinction between reconstructed anatomy and flow-related evidence.

Intrinsic Imaging’s venous-outflow medical device study distinguished duplex flow and diameter measurements, venographic stenosis grading and radiographic stent integrity assessment. Stent integrity and migration were assessed against a post-deployment baseline, while findings involving patency failure or integrity received additional review. This approach preserves the distinction between the implant’s structural appearance and the vascular status it is intended to maintain.

IVC filter trials can assess device position, penetration, tilt, fracture, migration and caval patency using explicitly defined measurements. Intrinsic Imaging’s Guidance distinguishes radiography for gross surveillance from CT venography for detailed complication endpoints. The imaging charter should define modality, follow-up timing and reading procedures, while follow-up completeness and retrieval-related imaging remain important parts of evaluating device performance rather than assuming all complications are symptomatic.

Intrinsic Imaging’s tumor-imaging platform case study describes a documented reference-standard hierarchy linking platform images, conventional comparator imaging and pathology or clinical follow-up. Readers recorded lesion-level malignancy assessments and confidence scores while blinded to the reference standard. Intrinsic Imaging’s charter defined how to handle multiple lesions and resolve disagreement between reference sources, preserving the evidentiary basis of each diagnostic classification.

Intrinsic Imaging’s tumor-ablation study linked pre-procedure, immediate post-procedure and follow-up examinations through centralized processing and co-registration. Readers measured the tumor and ablation zone in three dimensions, calculated the minimal margin and classified enhancement under charter-defined criteria. Coverage measurements and enhancement classifications address different questions, and the case explicitly distinguishes imaging appearances from direct histological confirmation of residual tumor.

Intrinsic Imaging’s readers interpret echocardiography (2D/3D), cardiac MRI and MRA, stress MRI, cardiac and vascular CTA, angiography, ECG, MUGA, PET, SPECT, nuclear cardiology, ultrasound and thoracic CT/MRI/HRCT.

Yes. Intrinsic Imaging’s Cardiovascular Imaging division supports clinical trials evaluating both cardiac safety and cardiovascular efficacy endpoints.

Intrinsic Imaging’s cardiovascular reads are performed by more than 150 board-certified, fellowship-trained cardiologists and cardiothoracic radiologists.

Reproducibility depends on consistent acquisition and analysis, not simply on selecting echocardiography as the modality. Intrinsic Imaging’s Guidance emphasizes standardized chamber quantification, sonographer training, consistent views and frame rates, and a small, consistent group of blinded central readers. Keeping each participant on the same vendor platform and software is particularly important for strain measurements, which can differ between systems.

Intrinsic Imaging’s Guidance recommends defining whether ultrasound contrast is mandatory or triggered by a prespecified image-quality threshold. The protocol should also specify the agent, dose, delivery method and imaging settings, while maintaining consistent contrast use across visits for each participant. Perfusion analysis is a separate consideration and is described as exploratory unless its role has been agreed with regulators.

No. A coronary calcium score quantifies calcification rather than directly measuring the degree of luminal narrowing. Intrinsic Imaging’s Guidance describes the Agatston score as an area-and-density-based measure associated with atherosclerotic plaque burden and cardiovascular risk. It also explains that greater calcium density can have a different risk association from greater calcium volume, making the selected biomarker and its interpretation important in longitudinal trials.

Quantitative MRI uses iron-related changes in transverse relaxation to assess tissue iron rather than relying solely on serum ferritin. Intrinsic Imaging’s Guidance explains that T2 and T2* shorten as iron increases, while the corresponding R2 and R2* relaxation rates rise. Liver iron concentration and cardiac T2* provide distinct information, particularly because serum ferritin correlates poorly with cardiac iron and can rise with inflammation or infection.

Intrinsic Imaging’s cystic fibrosis study used thoracic radiologists and a structured, lobe-based scoring system covering airway, parenchymal and air-trapping findings. Acquisition controls addressed inspiration, expiration and motion, while independent reads on a prespecified sample supported reproducibility assessment. Component scores were retained alongside totals because agreement on an overall score does not necessarily imply equal agreement on every underlying feature.

Intrinsic Imaging’s multicenter vascular medical device case describes three-dimensional CT angiography reconstruction for evaluating the spatial relationship between an implant and the vessel. The imaging charter defined how reconstructed anatomy contributed to deployment and surveillance endpoints, while primary assessments underwent independent double reading and adjudication. This approach supports consistent evaluation of implant configuration and position within the anatomy rather than relying on an isolated measurement plane.

Intrinsic Imaging’s neurological experience includes Alzheimer's disease and its variants, multiple sclerosis, Parkinson's disease, Huntington's disease, epilepsy, stroke and cerebrovascular disease, brain tumors, traumatic brain injury, spinal disorders, schizophrenia and other conditions.

Intrinsic Imaging’s CNS trial images are interpreted by more than 100 board-certified, fellowship-trained neuroradiologists.

Yes. Intrinsic Imaging supports CT and MR perfusion, diffusion and diffusion tensor imaging, and spectroscopy.

No. Volumetric and diffusion measures may serve as primary, secondary, safety or exploratory measures, depending on the protocol and supporting validation. Intrinsic Imaging defines the role of each measure and the analysis method with the sponsor before reads begin.

Intrinsic Imaging’s Guidance emphasizes a fixed three-dimensional T1 acquisition protocol, consistent scanner use for each participant and longitudinal segmentation. These controls help make serial volumetric assessments methodologically consistent across visits rather than allowing acquisition or analysis changes to complicate interpretation. The article places volumetric MRI within a broader imaging strategy that also addresses pathology confirmation, staging and treatment-related safety monitoring.

Dopamine-pathway functional imaging evaluates presynaptic nigrostriatal function rather than routine brain anatomy alone. Intrinsic Imaging’s Guidance distinguishes dopamine-transporter SPECT, which reflects striatal transporter density, from fluorodopa PET, which reflects decarboxylase activity and vesicular storage. The article discusses imaging for participant enrichment and quantitative assessment, with the agent, acquisition conditions and intended endpoint role defined in the protocol.

CT and MRI provide complementary descriptions of traumatic brain injury rather than interchangeable measurements. Intrinsic Imaging’s Guidance discusses structured baseline CT scoring for stratification and selected MRI sequences that reveal injuries not captured by CT, particularly in mild TBI. The imaging strategy should follow the trial question, with standardized variable definitions and imaging findings considered alongside clinical characterization rather than a severity grade alone.

Intrinsic Imaging’s acute ischemic stroke case study describes charter-defined ASPECTS scoring, infarct volume measurement, hemorrhagic transformation classification and recanalization grading. Neuroradiologists performed blinded reads, with double reading and adjudication for primary endpoint assessments and calibration against reference cases. These distinct assessment tasks require their own definitions and quality oversight; consistency in one classification does not establish equivalent reproducibility for every measurement.

Intrinsic Imaging’s glioblastoma case study describes standardized MRI acquisition and blinded neuroradiology review under RANO criteria. The imaging charter defined enhancing and non-enhancing disease, the pseudoprogression window and confirmation requirements, while relevant corticosteroid and clinical information informed assessment without revealing treatment allocation. Intrinsic Imaging used reference-case calibration and adjudication to apply those rules consistently when treatment-related changes resembled tumor progression.

Intrinsic Imaging’s gastrointestinal experience includes IBD, ulcerative colitis, GERD, IBS, short bowel syndrome, ulcers and related abdominal and pelvic conditions.

Yes. Intrinsic Imaging provides central review of endoscopy alongside CT, MRI and nuclear imaging.

Intrinsic Imaging’s gastroenterology trial data are reviewed by more than 35 board-certified, fellowship-trained gastroenterologists.

Intrinsic Imaging’s gastrointestinal study combined standardized ulcer measurement conventions with reader training and calibration against reference cases. Blinded dual-reader review and structured adjudication addressed discordant scores, while submission checks established whether recordings were complete and technically adequate. These methods distinguish the availability of scoreable endoscopic evidence from consistency in how readers apply the scoring definitions to that evidence.

MR elastography provides quantitative liver-stiffness measurements that can support fibrosis assessment and longitudinal research. Intrinsic Imaging’s Guidance distinguishes this stiffness information from MRI proton density fat fraction, which measures liver fat, and discusses combining the two in one examination. Fibrosis thresholds and analysis methods require prespecification because thresholds vary across populations; diagnostic performance does not by itself establish formal qualification as a trial surrogate endpoint.

Intrinsic Imaging’s five-year iron-overload case study describes vendor-specific multi-echo T2* acquisition and phantom-based scanner qualification and requalification. Fixed analysis conventions, longitudinal analyst assignment, reproducibility sampling and periodic recalibration supported measurement consistency over time. Intrinsic Imaging evaluated technical stability separately from treatment-related change, recognizing that scanner checks do not replace examination-level review for motion and other limitations.

Liver-directed therapy can produce necrosis or treatment-zone changes without immediate lesion shrinkage, complicating size-based assessment. Intrinsic Imaging’s Guidance describes these limitations after radioembolization, embolization and ablation, while retaining RECIST 1.1 as the regulatory anchor in its sponsor recommendations. Additional morphologic, viable-tumor or volumetric assessments require prespecification, including clear rules for treated zones and the study’s primary versus secondary endpoints.

Yes. Intrinsic Imaging supports osteoarthritis and rheumatoid arthritis trials, including endpoints for joint-space width, cartilage, structural progression and inflammation.

Yes. Intrinsic Imaging provides DXA and quantitative CT assessments as part of Intrinsic Imaging’s musculoskeletal and bone density imaging services.

Intrinsic Imaging’s musculoskeletal images are interpreted by more than 150 board-certified, fellowship-trained musculoskeletal radiologists.

Structural imaging describes joint changes, whereas symptom assessments address the participant’s clinical experience; the two should not be treated as interchangeable. Intrinsic Imaging’s Guidance notes that radiographic joint-space narrowing is a late finding that correlates poorly with symptoms. MRI can directly depict cartilage and other joint abnormalities, but structural endpoints still need study-specific justification and early discussion of their intended role in pivotal trials.

RAMRIS provides standardized semiquantitative assessment of inflammatory and structural findings in rheumatoid arthritis. Intrinsic Imaging’s Guidance describes scoring synovitis, osteitis and erosions in the wrist and metacarpophalangeal joints, with the updated framework also addressing joint-space narrowing and tenosynovitis. MRI can show inflammation and erosions earlier than radiography, making the selected scoring domains important when defining the trial’s imaging objectives.

A fracture-healing endpoint needs an explicit definition rather than an unspecified judgment that union has occurred. Intrinsic Imaging’s Guidance recommends prespecifying the scoring system, such as RUST or modified RUST, the union threshold and required radiographic views. Consistent positioning, scheduled imaging and an immediate postoperative baseline support reliability, while selective CT may help address equivocal or delayed union within a defined protocol.

Intrinsic Imaging’s orthopedic medical device study used calibrated flexion-extension radiographs to measure angular and translational motion, while CT assessment evaluated bridging bone formation under standardized criteria. Readers integrated these complementary findings into a documented fusion determination, with adjudication for disagreements about motion or fusion status. Positioning and calibration guidance addressed acquisition quality before the combined evidence reached central interpretation.

Intrinsic Imaging supports CT, MRI, PET/CT, SPECT, bone scintigraphy and ultrasound, including diffusion, perfusion, volumetric and quantitative PET methods, across Phase I through IV oncology studies.

Intrinsic Imaging supports all major oncology response criteria, including RECIST 1.1, iRECIST, mRECIST, irRC, Lugano, Cheson, Choi, RANO, RANO 2.0, Macdonald, PCWG3, PERCIST, IWCLL, BI-RADS and protocol-specific methodologies.

Yes. Intrinsic Imaging can configure separate assessments and data fields for multiple protocol-defined response frameworks within a single study, such as RECIST 1.1 and iRECIST. Intrinsic Imaging preserves the independent response rules and traceability of results for each framework.

Yes. Intrinsic Imaging’s oncology radiologists conduct blinded independent central review and adjudication under standardized, protocol-specific review methodologies.

Diffusion-weighted MRI provides information about water mobility and tumor cellularity that can complement measurements of lesion size. Intrinsic Imaging’s Guidance notes that changes in apparent diffusion coefficient may precede size changes, but interpretation depends on the tumor and acquisition conditions. Prespecified acquisition parameters, measurement methods and repeatability-based thresholds are important, particularly because necrosis, hemorrhage, low cellularity and artifacts can complicate assessment.

Intrinsic Imaging’s Guidance explains that immunotherapy can produce initial tumor enlargement or new lesions before a subsequent response. iRECIST distinguishes unconfirmed progression from confirmed progression, with confirmation imaging typically scheduled four to eight weeks later. The protocol should define confirmation requirements and eligibility for treatment beyond unconfirmed progression; the imaging category alone is not a treatment recommendation.

In mRECIST assessment of hepatocellular carcinoma, viable tumor refers to the enhancing tumor component rather than the entire lesion’s dimensions. Intrinsic Imaging’s Guidance explains why this distinction matters after locoregional or antiangiogenic therapy, when overall size may not capture the treatment effect. The applicable response framework and contrast acquisition should be specified for the study rather than treating mRECIST as a universal replacement for RECIST 1.1.

Lymphoma response assessment is not simply a solid-tumor size assessment applied to lymph nodes. Intrinsic Imaging’s Guidance identifies Lugano as the lymphoma framework, with FDG-PET and the Deauville five-point scale central to assessment of FDG-avid lymphomas. RECIST 1.1 remains the default framework for many solid-tumor trials, so the disease type and applicable response criteria need to be established before image review.

Intrinsic Imaging’s board-certified ophthalmologists have participated in more than 160 ophthalmology clinical trials as principal investigators or reviewers.

Yes. Intrinsic Imaging reviews OCT and fundus autofluorescence alongside color fundus photography, fluorescein angiography and adaptive optics imaging.

Yes. Intrinsic Imaging supports functional endpoints, including BCVA, visual fields, ERG, full-field stimulus testing and IOP.

Intrinsic Imaging’s diabetic macular edema study used certified graders to review automated segmentation and manually correct identified boundary errors. Defined criteria governed examinations with substantial segmentation failure or limited image quality, and the rationale for corrected, qualified or excluded measurements was documented. This approach makes the anatomical basis and technical limitations of central subfield thickness measurements inspectable rather than relying solely on device-generated output.

Intrinsic Imaging’s geographic atrophy case study describes uniform lesion delineation criteria, reference-case training and periodic reader recalibration. Readers recorded independent assessments before reviewing ambiguous boundaries together, and the final consensus and its rationale were documented alongside those initial judgments. Intrinsic Imaging retained traceability from each source image to the reported lesion area, supporting examination of how a longitudinal measurement was established.

A sponsor may consider transferring an imaging study to Intrinsic Imaging when missed read timelines, reader turnover, unresolved image queries or data reconciliation problems jeopardize trial milestones. Intrinsic Imaging evaluates the current imaging status, outstanding work and requirements for a controlled transition with the sponsor.

Yes. Intrinsic Imaging routinely assumes responsibility for imaging studies already in progress. Intrinsic Imaging’s transition process encompasses existing image archives and read data, charter alignment, reader training and site communications, with responsibilities and milestones documented before reads resume.

Intrinsic Imaging determines the study rescue schedule according to archive size, data completeness, charter alignment, outstanding queries and reader requirements. Intrinsic Imaging evaluates these dependencies with the sponsor and establishes a study-specific transition plan rather than applying a fixed timeline to every transfer.

Intrinsic Imaging receives the available image archive and read data, verifies completeness and de-identification, and reconciles the transferred records. Intrinsic Imaging’s physicians review the existing charter and read design to determine how earlier assessments and new reads can remain consistent and traceable.

Intrinsic Imaging’s CNS rescue case reviewed the previous charter, reading records and completed assessments before clarifying decision rules in a harmonized charter faithful to the existing methodology. Readers then trained on prior conventions and calibrated against previously assessed cases, with repeat-read samples monitoring agreement as review progressed. This illustrates methodological continuity rather than replacing historical interpretation rules with a new assessment framework.

No. Intrinsic Imaging determines whether previous images require rereading according to prior read quality, consistency of criteria, available source data and the study’s analysis requirements. Intrinsic Imaging documents the assessment and agrees any bridging or reread scope with the sponsor; a transfer does not automatically require rereading every image.

Intrinsic Imaging trains subspecialty readers on the protocol, response criteria and imaging charter. Intrinsic Imaging provides sites with updated acquisition guidance and upload instructions, together with operational support to resolve outstanding queries and establish the new image submission workflow.

Intrinsic Imaging’s Phase III solid-tumor rescue case describes targeted site retraining based on acquisition and submission deficiencies observed in earlier examinations. Site-level performance metrics then helped identify where those problems re-emerged after the transition. Intrinsic Imaging used these findings to direct additional intervention while ongoing enrollment and follow-up continued, linking corrective training to documented image-quality problems rather than applying an undifferentiated retraining program.

Intrinsic Imaging’s library contains 78 imaging core lab case studies spanning study rescue, oncology BICR, AI/CAD reader studies, medical devices, Cardiovascular & Thoracic, CNS, Gastroenterology & Metabolic, Musculoskeletal and Ophthalmology. Each case study examines a sponsor objective, an imaging challenge and the central review approach adopted by Intrinsic Imaging.

Intrinsic Imaging organizes case studies by category so that sponsors can focus on a therapeutic area or study type. When reviewing Intrinsic Imaging’s case studies, sponsors should also consider the imaging endpoint, acquisition modality, reader design and operational challenge, rather than the indication alone.

An Intrinsic Imaging press announcement provides a dated account of a study award, milestone or reported result, while a related case study explains the imaging challenge and review approach. Reciprocal links connect relevant announcements with their case narratives so that sponsors can examine both the original report and the operational context. Intrinsic Imaging preserves the distinction between historical study experience and the requirements of a prospective engagement.

No. Intrinsic Imaging’s case studies preserve sponsor confidentiality and do not disclose patient information. Intrinsic Imaging’s library focuses on imaging objectives, review strategies and study execution rather than identifying sponsors or individual participants.

Yes. An Intrinsic Imaging case study can provide a valuable starting point, but the imaging workflow must be tailored to the new protocol. Intrinsic Imaging defines acquisition requirements, assessment criteria, reader expertise, blinding and data delivery around the sponsor’s specific endpoints and study population.

No. Intrinsic Imaging’s case studies illustrate experience from particular imaging engagements rather than commitments to repeat their timelines, scale or outcomes. Each new study has its own protocol, imaging population, acquisition requirements and review dependencies. Intrinsic Imaging agrees the scope, milestones and deliverables with the sponsor for the prospective engagement, using relevant case experience to inform planning rather than replace study-specific evaluation.

Yes. Intrinsic Imaging’s team can review a sponsor’s protocol, imaging endpoints, study timeline and current operational challenges to determine an appropriate scope of support. For an ongoing trial, discussions with Intrinsic Imaging can also address archive transfer, outstanding reads and transition requirements.

Intrinsic Imaging’s Imaging Guidance for Sponsors provides scientific context for selecting imaging methods, response criteria and acquisition controls. Articles describing the evolution of RECIST, iRECIST, Lugano and treatment-specific frameworks help sponsors understand why the assessment approach must fit the disease and therapeutic mechanism. Historical publications should be considered alongside current evidence and the planned study’s objectives, with the applicable criteria and review procedures defined prospectively in the protocol and imaging charter.